3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1
2
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
5
Stomach Neoplasms
4
HER2-positive Breast Cancer
3
Neoplasms
2
Hematologic Neoplasms
2
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoproliferative Disorders
1
Lung Neoplasms
1
HER2-positive Gastric Cancer
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Gemcitabine
5
Cisplatin
5
Oxaliplatin
2
pertuzumab
1
durvalumab
1
Trastuzumab
1
Standard of Care
1
Radiotherapy, Intensity-Modulated
1
Platinum
1
Paclitaxel
1
Magnetic Resonance Spectroscopy
1
Lymph Node Excision
1
Laparoscopy
1
Geriatric Assessment
1
Everolimus
1
Drug Therapy
1
Chemoradiotherapy
1
Capecitabine
1
ARRY-334543
1
130-nm albumin-bound paclitaxel
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Gallbladder Neoplasms
×
Trastuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled